Literature DB >> 25223977

Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.

Nemat Khan1, Trent M Woodruff2, Maree T Smith3.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that causes debilitating central neuropathic pain in many patients. Although mouse models of experimental autoimmune encephalomyelitis (EAE) have provided insight on the pathobiology of MS-induced neuropathic pain, concurrent severe motor impairments confound quantitative assessment of pain behaviors over the disease course. To address this issue, we have established and characterized an optimized EAE-mouse model of MS-induced neuropathic pain. Briefly, C57BL/6 mice were immunized with MOG35-55 (200μg) and adjuvants comprising Quil A (45μg) and pertussis toxin (2×250ng). The traditionally used Freund's Complete Adjuvant (FCA) was replaced with Quil A, as FCA itself induces CNS neuroinflammation. Herein, EAE-mice exhibited a mild relapsing-remitting clinical disease course with temporal development of mechanical allodynia in the bilateral hindpaws. Mechanical allodynia was fully developed by 28-30days post-immunization (p.i.) and was maintained until study completion (52-60days p.i.), in the absence of confounding motor deficits. Single bolus doses of amitriptyline (1-7mg/kg), gabapentin (10-50mg/kg) and morphine (0.1-2mg/kg) evoked dose-dependent analgesia in the bilateral hindpaws of EAE-mice; the corresponding ED50s were 1.5, 20 and 1mg/kg respectively. At day 39 p.i. in EAE-mice exhibiting mechanical allodynia in the hindpaws, there was marked demyelination and gliosis in the brain and lumbar spinal cord, mirroring these pathobiologic hallmark features of MS in humans. Our optimized EAE-mouse model of MS-associated neuropathic pain will be invaluable for future investigation of the pathobiology of MS-induced neuropathic pain and for efficacy profiling of novel molecules as potential new analgesics for improved relief of this condition.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesia; Experimental autoimmune encephalomyelitis (EAE); Mechanical allodynia; Multiple sclerosis (MS); Neuroinflammation; Neuropathic pain

Mesh:

Substances:

Year:  2014        PMID: 25223977     DOI: 10.1016/j.pbb.2014.09.003

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  The role of G-protein receptor 84 in experimental neuropathic pain.

Authors:  Louise S C Nicol; John M Dawes; Federica La Russa; Athanasios Didangelos; Anna K Clark; Clive Gentry; John Grist; John B Davies; Marzia Malcangio; Stephen B McMahon
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

2.  Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy.

Authors:  Peter M Grace; Lisa C Loram; John P Christianson; Keith A Strand; Johanna G Flyer-Adams; Kathryn R Penzkover; John R Forsayeth; Anne-Marie van Dam; Melissa J Mahoney; Steven F Maier; Raymond A Chavez; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2016-05-14       Impact factor: 7.217

3.  Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain.

Authors:  Nemat Khan; Andy Kuo; David A Brockman; Matthew A Cooper; Maree T Smith
Journal:  Inflammopharmacology       Date:  2017-09-30       Impact factor: 4.473

4.  Antipsychotics, versatility in action.

Authors:  Sidharth Mahapatra; Tiago Reis Marques
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-13       Impact factor: 11.205

5.  Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn.

Authors:  Suzanne Doolen; Tommaso Iannitti; Renee R Donahue; Benjamin C Shaw; Carolyn M Grachen; Bradley K Taylor
Journal:  Pain       Date:  2018-02       Impact factor: 7.926

6.  Antiallodynic effects of alpha lipoic acid in an optimized RR-EAE mouse model of MS-neuropathic pain are accompanied by attenuation of upregulated BDNF-TrkB-ERK signaling in the dorsal horn of the spinal cord.

Authors:  Nemat Khan; Richard Gordon; Trent M Woodruff; Maree T Smith
Journal:  Pharmacol Res Perspect       Date:  2015-05-04

7.  Yokukansan (Kampo medicinal formula) prevents the development of morphine tolerance by inhibiting the secretion of orexin A.

Authors:  Ayami Katayama; Yasuaki Kanada; Mana Tsukada; Yuko Akanuma; Haruka Takemura; Takahiro Ono; Hiroki Suga; Hitoshi Mera; Tadashi Hisamitsu; Masataka Sunagawa
Journal:  Integr Med Res       Date:  2018-03-08

Review 8.  TNFα in MS and Its Animal Models: Implications for Chronic Pain in the Disease.

Authors:  Aislinn D Maguire; John R Bethea; Bradley J Kerr
Journal:  Front Neurol       Date:  2021-12-06       Impact factor: 4.003

9.  The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.

Authors:  Priyank A Shenoy; Andy Kuo; Nemat Khan; Louise Gorham; Janet R Nicholson; Laura Corradini; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

Review 10.  Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models.

Authors:  Eleni Stamoula; Spyridon Siafis; Ioannis Dardalas; Alexandra Ainatzoglou; Alkis Matsas; Theodoros Athanasiadis; Chrysanthi Sardeli; Konstantinos Stamoulas; Georgios Papazisis
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.